AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 Oct 2020 03:00 PM
RNS
Total Voting Rights
25 Sep 2020 07:00 AM
RNS
Directorate Change
21 Sep 2020 07:05 AM
RNS
Lynparza EU recommendation in prostate cancer
21 Sep 2020 07:00 AM
RNS
Lynparza EU recommendation in ovarian cancer
21 Sep 2020 07:00 AM
RNS
Tagrisso reduced early lung cancer brain recurrenc
10 Sep 2020 07:01 AM
RNS
AstraZeneca to list all US securities on Nasdaq
10 Sep 2020 07:00 AM
RNS
Fasenra PhIII OSTRO trial met co-primary endpoints
01 Sep 2020 03:00 PM
RNS
Total Voting Rights
01 Sep 2020 07:00 AM
RNS
Imfinzi approved in EU for small cell lung cancer
01 Sep 2020 07:00 AM
RNS
Farxiga reduces CKD progression and risk of death
25 Aug 2020 07:00 AM
RNS
Ph I trial begins for COVID-19 monoclonal antibody
21 Aug 2020 07:00 AM
RNS
Imfinzi approved in Japan for SCLC
18 Aug 2020 07:00 AM
RNS
Imfinzi US Priority Review; four-week, fixed dose
04 Aug 2020 07:00 AM
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2020 03:00 PM
RNS
Total Voting Rights
30 Jul 2020 07:25 AM
RNS
Tagrisso US BTD for EGFRm adjuvant lung cancer
30 Jul 2020 07:18 AM
RNS
AZN: H1 2020 results
29 Jul 2020 07:00 AM
RNS
Board Committee Changes
28 Jul 2020 07:00 AM
RNS
Farxiga DAPA-CKD trial met all endpoints
27 Jul 2020 07:10 AM
RNS
Calquence receives positive CHMP opinion for CLL
27 Jul 2020 07:05 AM
RNS
Imfinzi recommended for EU approval in SCLC
27 Jul 2020 07:00 AM
RNS
AstraZeneca enters collaboration in oncology
24 Jul 2020 07:00 AM
RNS
Breztri Aerosphere approved in the US for COPD
22 Jul 2020 03:00 PM
RNS
Holding(s) in Company
22 Jul 2020 03:00 PM
RNS
Holding(s) in Company
21 Jul 2020 03:00 PM
RNS
Holding(s) in Company
21 Jul 2020 03:00 PM
RNS
Holding(s) in Company
20 Jul 2020 02:41 PM
RNS
COVID-19 vaccine Phase I/II showed immune response
16 Jul 2020 07:00 AM
RNS
Director Declaration
09 Jul 2020 07:00 AM
RNS
Brilinta granted US FDA Priority Review for stroke
08 Jul 2020 07:00 AM
RNS
Lynparza approved in the EU for pancreatic cancer
01 Jul 2020 03:00 PM
RNS
Total Voting Rights
30 Jun 2020 03:00 PM
RNS
Director/PDMR Shareholding
30 Jun 2020 07:00 AM
RNS
Selumetinib granted Japan orphan drug designation
17 Jun 2020 03:03 PM
RNS
Holding(s) in Company
17 Jun 2020 03:00 PM
RNS
Holding(s) in Company
15 Jun 2020 07:00 AM
RNS
Agreement to Supply Europe with COVID-19 Vaccine
11 Jun 2020 07:00 AM
RNS
EMTN Programme Routine Technical Update
01 Jun 2020 03:00 PM
RNS
Block listing Interim Review
01 Jun 2020 03:00 PM
RNS
Total Voting Rights
01 Jun 2020 07:00 AM
RNS
Brilinta obtains additional US approval
01 Jun 2020 07:00 AM
RNS
Lynparza EU CHMP opinion in pancreatic cancer
29 May 2020 04:41 PM
RNS
Second Price Monitoring Extn
29 May 2020 04:35 PM
RNS
Price Monitoring Extension
29 May 2020 01:00 PM
RNS
Enhertu DESTINY-Gastric01 results from ASCO 2020
29 May 2020 01:00 PM
RNS
Imfinzi sustained overall survival in CASPIAN
29 May 2020 07:00 AM
RNS
Tagrisso unprecedented adjuvant lung cancer data
26 May 2020 10:30 AM
RNS
Director/PDMR Shareholding
22 May 2020 07:00 AM
RNS
Enhertu US orphan designation in gastric cancer
21 May 2020 07:00 AM
RNS
AstraZeneca advances response to COVID-19 outbreak
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100